Table 2.
Efficacy of transmission prophylaxis with HIG
| Trimester of maternal primary infection | Transmission rate without treatment % (n/n) | Transmission rate under HIG treatment | P |
|---|---|---|---|
| a. Overall transmission (detected by AC and/or urine of neonate) | |||
| First trimester1 (n = 33) | 35.2% (38/108) | 24.2% (8/33) | 0.169 |
| Second trimester2 (n = 12) | 42.0% (42/100) | 16.7% (2/12) | 0.079 |
| Third trimester2 (n = 1) | 58.6% (17/29) | 100% (1/1) | 0.600 |
| Overall2 (n = 46) | 39.9% (112/281) | 23.9% (11/46) | 0.026* |
| b. Transmission before 23 weeks gestation (detected by AC) under HIG treatment compared by study | |||
| Kagan et al | 35.2%1 (38/108) | 2.5% (1/40) | < 0.000010* |
| Our cohort | 7.1% (1/14) | 0.027* | |
| c. Overall transmission rate under HIG treatment when HIG was administered within 21 days after first suspicious lab result compared by study | |||
| Kagan et al | 39.9%2 (112/281) | 7.5% (3/40) | < 0.000015* |
| Our cohort | 19.2% (5/26) | 0.028* | |
AC amniocentesis, HIG hyperimmunoglobulin
1Data from Kagan et al
2Data from Feldman et al
P values in one-sided Fisher’s exact test. Statistically significant (P ≤ 0.05) shown asterisked